Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker.

BACKGROUND Cardiac pacemakers are limited by device-related complications, notably infection and problems related to pacemaker leads. We studied a miniaturized, fully self-contained leadless pacemaker that is nonsurgically implanted in the right ventricle with the use of a catheter. METHODS In this multicenter study, we implanted an active-fixation leadless cardiac pacemaker in patients who required permanent single-chamber ventricular pacing. The primary efficacy end point was both an acceptable pacing threshold (≤2.0 V at 0.4 msec) and an acceptable sensing amplitude (R wave ≥5.0 mV, or a value equal to or greater than the value at implantation) through 6 months. The primary safety end point was freedom from device-related serious adverse events through 6 months. In this ongoing study, the prespecified analysis of the primary end points was performed on data from the first 300 patients who completed 6 months of follow-up (primary cohort). The rates of the efficacy end point and safety end point were compared with performance goals (based on historical data) of 85% and 86%, respectively. Additional outcomes were assessed in all 526 patients who were enrolled as of June 2015 (the total cohort). RESULTS The leadless pacemaker was successfully implanted in 504 of the 526 patients in the total cohort (95.8%). The intention-to-treat primary efficacy end point was met in 270 of the 300 patients in the primary cohort (90.0%; 95% confidence interval [CI], 86.0 to 93.2, P=0.007), and the primary safety end point was met in 280 of the 300 patients (93.3%; 95% CI, 89.9 to 95.9; P<0.001). At 6 months, device-related serious adverse events were observed in 6.7% of the patients; events included device dislodgement with percutaneous retrieval (in 1.7%), cardiac perforation (in 1.3%), and pacing-threshold elevation requiring percutaneous retrieval and device replacement (in 1.3%). CONCLUSIONS The leadless cardiac pacemaker met prespecified pacing and sensing requirements in the large majority of patients. Device-related serious adverse events occurred in approximately 1 in 15 patients. (Funded by St. Jude Medical; LEADLESS II ClinicalTrials.gov number, NCT02030418.).

[1]  Lluís Mont,et al.  Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study , 2015, European heart journal.

[2]  P. Karjalainen,et al.  Venous Obstruction After Pacemaker Implantation , 2007, Pacing and clinical electrophysiology : PACE.

[3]  Ellen Aagaard Nohr,et al.  Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark , 2013, European heart journal.

[4]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[5]  Peter Hunold,et al.  Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. , 2011, Heart rhythm.

[6]  Karel G M Moons,et al.  Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. , 2012, Heart rhythm.

[7]  H. Frumin,et al.  Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. , 2000, The American journal of cardiology.

[8]  Jagmeet P. Singh,et al.  Increased Perforation Risk with an MRI‐Conditional Pacing Lead: A Single‐Center Study , 2015, Pacing and clinical electrophysiology : PACE.

[9]  L. Goldman,et al.  Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. , 2002, The New England journal of medicine.

[10]  K. Chan,et al.  Prevalence and mechanism of tricuspid regurgitation following implantation of endocardial leads for pacemaker or cardioverter-defibrillator. , 2012, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[11]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[12]  Arthur A M Wilde,et al.  Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial. , 2015, Journal of the American College of Cardiology.

[13]  H. Mond,et al.  The 11th World Survey of Cardiac Pacing and Implantable Cardioverter‐Defibrillators: Calendar Year 2009–A World Society of Arrhythmia's Project , 2011, Pacing and clinical electrophysiology : PACE.

[14]  David L Hayes,et al.  Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. , 2007, Heart rhythm.

[15]  J. Nielsen,et al.  Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients , 2011, European heart journal.

[16]  L. Goldman,et al.  Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing: Meta-Analysis of Randomized Trials, Using Individual Patient Data , 2006, Circulation.

[17]  David L Hayes,et al.  Incidence and predictors of cardiac perforation after permanent pacemaker placement. , 2005, Heart rhythm.

[18]  M. Zaccaria,et al.  Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  Arthur A M Wilde,et al.  Permanent Leadless Cardiac Pacing: Results of the LEADLESS Trial , 2014, Circulation.

[20]  Z. Emkanjoo,et al.  Predictors of venous obstruction following pacemaker or implantable cardioverter-defibrillator implantation: a contrast venographic study on 100 patients admitted for generator change, lead revision, or device upgrade. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  Jacques Victor,et al.  Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-Defibrillators: Results of a Large Prospective Study , 2007, Circulation.

[22]  Christopher A. Aakre,et al.  Stroke or Transient Ischemic Attack in Patients With Transvenous Pacemaker or Defibrillator and Echocardiographically Detected Patent Foramen Ovale , 2013, Circulation.